BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 7545459)

  • 1. Combined transplantation of allogeneic bone marrow and CD34+ blood cells.
    Link H; Arseniev L; Bähre O; Berenson RJ; Battmer K; Kadar JG; Jacobs R; Casper J; Kühl J; Schubert J; Diedrich H; Poliwoda H
    Blood; 1995 Oct; 86(7):2500-8. PubMed ID: 7545459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transplantation of allogeneic CD34+ blood cells.
    Link H; Arseniev L; Bähre O; Kadar JG; Diedrich H; Poliwoda H
    Blood; 1996 Jun; 87(11):4903-9. PubMed ID: 8639865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of poor marrow graft function with allogeneic CD34+ cells immunoselected from G-CSF-mobilized peripheral blood progenitor cells of the marrow donor.
    Arseniev L; Tischler HJ; Battmer K; Südmeier I; Casper J; Link H
    Bone Marrow Transplant; 1994 Nov; 14(5):791-7. PubMed ID: 7534162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic bone marrow transplantation for chronic myeloid leukemia using HLA identical sibling donors primed with G-CSF.
    Chen HR; Ji SQ; Wang HX; Yan HM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2002 Aug; 10(4):340-6. PubMed ID: 12513770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the content and subpopulations of CD3 and CD34 positive cells in bone marrow harvests and G-CSF-mobilized peripheral blood leukapheresis products from healthy adult donors.
    Hassan HT; Stockschläder M; Schleimer B; Krüger W; Zander AR
    Transpl Immunol; 1996 Dec; 4(4):319-23. PubMed ID: 8972563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies.
    Cao TM; Kusnierz-Glaz C; Valone F; Stockerl-Goldstein KE; Hu WW; Johnston L; Blume KG; Strober S; Negrin RS
    Cancer; 2001 Jun; 91(12):2205-13. PubMed ID: 11413507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of outcome of allogeneic bone marrow transplantation with and without granulocyte colony-stimulating factor (lenograstim) donor-marrow priming in patients with chronic myelogenous leukemia.
    Ji SQ; Chen HR; Wang HX; Yan HM; Pan SP; Xun CQ
    Biol Blood Marrow Transplant; 2002; 8(5):261-7. PubMed ID: 12064363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation.
    Lemoli RM; Bandini G; Leopardi G; Rosti G; Bonini A; Fortuna A; Rondelli D; Mangianti S; Motta MR; Rizzi S; Tassi C; Cavo M; Remiddi C; Curti A; Conte R; Tura S
    Haematologica; 1998 Jan; 83(1):48-55. PubMed ID: 9542323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transplantation of allogeneic CD34+ peripheral blood stem cells in patients with advanced hematologic malignancy.
    Bensinger WI; Buckner CD; Shannon-Dorcy K; Rowley S; Appelbaum FR; Benyunes M; Clift R; Martin P; Demirer T; Storb R; Lee M; Schiller G
    Blood; 1996 Dec; 88(11):4132-8. PubMed ID: 8943847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Allogeneic hematopoietic transplantation with stem cells extracted from peripheral blood].
    Kusminsky G; Foncuberta MC; Aversa L; Drelichman G; Freigeiro D; Burgos R; Irrazabal C; Gonzalez G; Dictar M; Niborski R; Kohan A; Sanchez Avalos JC
    Medicina (B Aires); 2000; 60(2):179-87. PubMed ID: 10962806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease.
    Körbling M; Huh YO; Durett A; Mirza N; Miller P; Engel H; Anderlini P; van Besien K; Andreeff M; Przepiorka D; Deisseroth AB; Champlin RE
    Blood; 1995 Oct; 86(7):2842-8. PubMed ID: 7545476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Granulocyte-colony-stimulating factor (G-CSF)-primed allogeneic bone marrow: significantly less graft-versus-host disease and comparable engraftment to G-CSF-mobilized peripheral blood stem cells.
    Morton J; Hutchins C; Durrant S
    Blood; 2001 Dec; 98(12):3186-91. PubMed ID: 11719353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The addition of allogeneic peripheral blood-derived progenitor cells to bone marrow for transplantation: results of a randomised clinical trial.
    Szer J; Curtis DJ; Bardy PG; Grigg AP
    Aust N Z J Med; 1999 Aug; 29(4):487-93. PubMed ID: 10868525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid engraftment without significant graft-versus-host disease after allogeneic transplantation of CD34+ selected cells from peripheral blood.
    Urbano-Ispizua A; Rozman C; Martínez C; Marín P; Briones J; Rovira M; Féliz P; Viguria MC; Merino A; Sierra J; Mazzara R; Carreras E; Montserrat E
    Blood; 1997 Jun; 89(11):3967-73. PubMed ID: 9166834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors influencing the haematological recovery after allogeneic bone marrow transplantation in leukaemia patients treated with methotrexate-containing GVHD prophylaxis: a single-centre experience.
    Hassan HT; Krog C; Stockschläder M; Schleimer B; Zeller W; Krüger W; Erttmann R; Zander AR
    Anticancer Res; 1997; 17(1B):589-99. PubMed ID: 9066585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Technical and safety aspects of blood and marrow transplantation using G-CSF mobilized family donors.
    Kadar JG; Arseniev L; Schnitger K; Südmeier I; Zaki M; Battmer K; Jacobs R; Diedrich H; Poliwoda H; Stangel W; Link H
    Transfus Sci; 1996 Dec; 17(4):611-8. PubMed ID: 10168561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor).
    Schmitz N; Dreger P; Suttorp M; Rohwedder EB; Haferlach T; Löffler H; Hunter A; Russell NH
    Blood; 1995 Mar; 85(6):1666-72. PubMed ID: 7534141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T cell-depleted granulocyte colony-stimulating factor (G-CSF) modified allogenic bone marrow transplantation for hematological malignancy improves graft CD34+ cell content but is associated with delayed pancytopenia.
    Mavroudis DA; Read EJ; Molldrem J; Raptis A; Plante M; Carter CS; Phang S; Dunbar CE; Barrett AJ
    Bone Marrow Transplant; 1998 Mar; 21(5):431-40. PubMed ID: 9535034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized multicenter comparison of CD34(+)-selected progenitor cells from blood vs from bone marrow in recipients of HLA-identical allogeneic transplants for hematological malignancies.
    Cornelissen JJ; van der Holt B; Petersen EJ; Vindelov L; Russel CA; Höglund M; Maertens J; Schouten HC; Braakman E; Steijaert MM; Zijlmans MJ; Slaper-Cortenbach I; Boogaerts MA; Löwenberg B; Verdonck LF
    Exp Hematol; 2003 Oct; 31(10):855-64. PubMed ID: 14550800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic transplantation of selected CD34+ cells from peripheral blood: experience of 62 cases using immunoadsorption or immunomagnetic technique. Spanish Group of Allo-PBT.
    Urbano-Ispizua A; Solano C; Brunet S; de la Rubia J; Odriozola J; Zuazu J; Figuera A; Caballero D; Martínez C; García J; Sanz G; Torrabadella M; Alegre A; Pérez-Oteiza J; Jurado M; Oyonarte S; Sierra J; García-Conde J; Rozman C
    Bone Marrow Transplant; 1998 Sep; 22(6):519-25. PubMed ID: 9758337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.